Pharmaceutical heavyweight Novo Nordisk on Tuesday announced it is cutting prices for several insulin drugs in the U.S.
it is cutting prices for several insulin drugs in the U.S., following a similar move from drugmaker Eli Lilly as healthcare companies come under increasing pressure to lower prices for the lifesaving diabetes medication.Key Facts
Novo Nordisk said it will lower list prices for several insulin products—which includes vials, pre-mix insulins and pre-filled pens—by up to 75% starting January 2024. The company said it will cut the list price of its NovoLog insulin by 75% and prices for its Novolin and Levemir products by 65%. Novo Nordisk also said it will reduce list prices for unbranded insulin products to match the lowered price of the respective branded product.
Steve Albers, a senior vice president at Novo Nordisk, said the company is “working to develop a sustainable path forward that balances patient affordability, market dynamics, and evolving policy changes" and takes its responsibility to ensure patients can afford its products “seriously.”the company had been working on the change for months but “accelerated” its plans and announced them now due to increased stakeholder interest in the issue.
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyNovo Nordisk, along with Sanofi and Eli Lilly, make up most of the U.S. insulin market.
Lire la suite »
Novo Nordisk Will Lower Insulin Prices Up To 75%, Following Eli LillyNovo Nordisk, along with Sanofi and Eli Lilly, make up most of the U.S. insulin market.
Lire la suite »
Following Eli Lilly, drugmaker Novo Nordisk announces cuts to insulin pricesBREAKING: Novo Nordisk says it will lower the U.S. list price of some of its insulin products by up to 75% starting Jan. 1, 2024, following a similar move by Eli Lilly.
Lire la suite »
Novo Nordisk plans to cut insulin prices up to 75%, following Eli LillyNovo will reduce the list price for NovoLog and NovoLog Mix 70/30 by 75%, and cut Novolin and Levemir’s list prices by 65% — but not until 2024.
Lire la suite »
Novo Nordisk to slash U.S. insulin prices by up to 75%, following move by Eli LillyNovo Nordisk is planning to slash the price of several insulin drugs by up to 75% in the U.S., following a similar move by Eli Lilly.
Lire la suite »
Novo Nordisk to slash US insulin prices, following move by Eli LillyNovo Nordisk said on Tuesday it would cut U.S. list prices for several insulin products by up to 75% next year, joining rival Eli Lilly and Co as political pressure mounts to make these life-sustaining diabetes treatments more affordable.
Lire la suite »